ArriVent BioPharma, Inc. (AVBP) Publishes Phase 1b Data on Firmonertinib in Cancer Cell

ArriVent BioPharma (NASDAQ:AVBP) will present Phase 1 data for ARR-217, a CDH17-directed antibody-drug conjugate, at ESMO Congress 2026. The study focuses on patients with gastrointestinal cancers and was selected as a late-breaking oral presentation. ArriVent obtained exclusive rights to ARR-217 outside Greater China through a collaboration with Lepu Biopharma. The company will host a virtual webinar to discuss the data and program.

ArriVent BioPharma (Nasdaq: AVBP) announced that initial safety and efficacy data from its Phase 1 study of ARR-217, a CDH17-targeted ADC for gastrointestinal cancers, will be presented at ESMO Congress 2026. The company will host a webinar on October 26, 2026, to discuss the data. ARR-217 is ArriVent's lead clinical candidate, obtained via a collaboration with Lepu Biopharma.

ArriVent BioPharma published Phase 1b results in Cancer Cell, showing firmonertinib achieved ORR of 43% at 160 mg and 68% at 240 mg in EGFR PACC NSCLC, with median PFS of 11.1 and 16.0 months. The study also reported 47% intracranial ORR and 80% ctDNA clearance by cycle 3. Safety was consistent with prior studies. The company is progressing a global Phase 3 ALPACCA trial.

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer NEWTOWN SQUARE, PA, October 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedic

ArriVent BioPharma (AVBP) reported Phase 1b trial results for firmonertinib, showing 43% and 68% response rates at different doses in EGFR PACC-mutant NSCLC. The drug demonstrated intracranial activity and manageable safety. ArriVent is advancing a Phase 3 trial (ALPACCA) for this underserved lung cancer population, with no current standard treatment.

ArriVent BioPharma dosed the first U.S. patient in a Phase 1 trial of ARR-002, a dual-target ADC for ovarian and endometrial cancer. Preclinical data showed ARR-002 outperformed bivalent ADCs. ArriVent licensed ARR-002 to Shanghai Allist for Greater China in August 2026.